Industry Partners

These pages are for pharmaceutical companies interested in collaborating with the Glo-BNHL trial and submitting an asset for assessment and prioritisation.

In order to return a formal response within 4 weeks, please submit asset information to Glo-BNHL@trials.bham.ac.uk by the following dates:

 Month - Year Submission DeadlineFormal Response Date 
 Jan-2025  02-Jan-2025  30-Jan-2025
 Feb-2025  06-Feb-2025  06-Mar-2025
 Mar-2025  06-Mar-2025  03-Apr-2025
 Apr-2025  03-Apr-2025  01-May-2025
 May-2025  01-May-2025  29-May-2025
 Jun-2025  05-Jun-2025  03-Jul-2025
 Jul-2025  03-Jul-2025  31-Jul-2025
 Aug-2025  07-Aug-2025  04-Sep-2025
 Sep-2025  04-Sep-2025  02-Oct-2025
 Oct-2025  02-Oct-2025  30-Oct-2025
 Nov-2025  06-Nov-2025  04-Dec-2025
 Dec-2025  04-Dec-2025  01-Jan-2026
Open all sections

Asset Submission

Information regarding a potential asset for consideration for inclusion in the trial should be submitted electronically to the trial mailbox: Glo-BNHL@trials.bham.ac.uk.

This documentation should include a completed Asset Submission Form (downloadable below) and additional detailed information (in any suitable format) covering the following information:

Primary Target

  • Mechanism-of-action and scientific rationale for the target

Pre-clinical data 

  • Details of cell lines and models used
  • Concentration range tested and relation to human dosing
  • Observed responses and validation

Clinical Data

  • Safety data in adults including severity and frequency of Adverse Events, ability to support/modify toxicity and details of population in whom tested
  • Efficacy data in adults including details of tumour types, population, dosing regimens, study design and end-points
  • Any early safety/efficacy data in paediatrics if available (any disease)

Feasibility in Paediatrics

  • Plans for development of paediatric formulation (if applicable)
  • Pharmacokinetic studies or modelling supporting starting dose decision in children (if available)

Post-acceptance Process

Contractual Arrangements

Collaboration Agreements with industry partners with prioritised assets will be put into place with University of Birmingham (Sponsor). The University will enter into separate agreements with associated third-parties. This includes, but is not limited to:

      • Chief Investigator
      • National Coordinating Centres
      • Participating UK Centres
      • Vendors providing clinical trial services
      • Other academic collaborators for adjunctive scientific studies
      • Other industry partners with prioritised assets

There will be two agreements made with the industry partners: a start-up agreement and a main collaboration agreement.

The start-up agreement and associated budget will include all start-up activity costs associated with the initial work-up in preparation for inclusion of the asset into the trial and should be executed rapidly with any amendments restricted to administrative changes only.

The main Collaboration Agreement between the parties will be negotiated once the start-up agreement is finalised. A commitment to execute both agreements in an expedited fashion is imperative to ensure the smooth running of the trial. A videoconference every two weeks between the legal teams of the Sponsor and industry partner will be scheduled following acceptance of an asset into the trial.

Quality Management

The CRCTU holds an extensive Quality Management System covering all aspects of clinical trial management from design through to study closure and archiving.

Data Management

Data will be entered directly by participating centres into a 21 CFR Part 11 compliant electronic Data Capture (EDC) system. Data management will be conducted by the CRCTU. 

Country and Site Management 

The CRCTU has a well-established network of paediatric centres across the globe with the expertise to deliver complex, early phase trials in oncology. As Sponsor, University of Birmingham (UoB) delegates all country-specific activities to a National Coordinating Centre (NCC) in each country. This is a lead institution that is delegated some of the Sponsor responsibility for the trial within the respective country. NCCs are responsible for obtaining and maintaining regulatory approvals within the country, identifying sites, and managing the trial conduct. As Sponsor, the UoB through the CRCTU, will retain oversight of the conduct of NCCs. UK centres will be managed directly by CRCTU. 

CRCTU Requirements

To manage the study efficiently, the CRCTU will require the following information, including any future updates, where applicable:

  • Investigator’s Brochure
  • IMP Dossier or cross-referral letter
  • Details of supply, labelling and manufacture of the asset
  • Accepted safety information/language relating to the asset